Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
Stocks | Futures | Watchlist | More
or

Pacira Pharm Inc (PCRX)

Pacira Pharm Inc (PCRX)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Quote Overview for [[ item.sessionDateDisplayLong ]]
[[ rowChartData.labelLow ]]
[[ rowChartData.lowPriceFormatted ]]
[[ rowChartData.lowPrice ]]
[[ rowChartData.labelHigh ]]
[[ rowChartData.highPriceFormatted ]]
[[ rowChartData.highPrice ]]
since [[ rowChartData.lowDate ]]
since [[ rowChartData.highDate ]]
[[ value ]] [[ value ]]
Realtime quote and/or trades are not sourced from all markets.

Fundamentals

See More
  • Market Capitalization, $K 1,900,429
  • Shares Outstanding, K 41,731
  • Annual Sales, $ 337,280 K
  • Annual Income, $ -470 K
  • 60-Month Beta 1.17
  • Price/Sales 5.71
  • Price/Cash Flow 48.31
  • Price/Book 5.55

Analyst Rating / Earnings Estimates

Current Rating
See More
Moderate Buy
Based on 12 analysts offering recommendations.
Earnings Estimates - Current Qtr 12/31/19
See More
  • Average Estimate 0.19
  • Number of Estimates 6
  • High Estimate 0.28
  • Low Estimate 0.10
  • Prior Year 0.28
  • Growth Rate Est. (year over year) -32.14%

Price Performance

See More
Period Period Low Period High Performance
1-Month
42.20 +7.91%
on 11/15/19
46.85 -2.80%
on 12/03/19
+2.03 (+4.67%)
since 11/11/19
3-Month
35.45 +28.46%
on 10/03/19
46.85 -2.80%
on 12/03/19
+8.13 (+21.73%)
since 09/11/19
52-Week
34.64 +31.47%
on 09/09/19
49.50 -8.00%
on 05/03/19
-1.46 (-3.11%)
since 12/11/18

Most Recent Stories

More News
ASRT vs. PCRX: Which Stock Should Value Investors Buy Now?

ASRT vs. PCRX: Which Stock Is the Better Value Option?

ASRT : 0.79 (+2.41%)
PCRX : 45.54 (-1.39%)
Pacira (PCRX) Up 7.6% Since Last Earnings Report: Can It Continue?

Pacira (PCRX) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

PCRX : 45.54 (-1.39%)
16.0% Return Seen to Date on SmarTrend Pacira Pharmaceu Call (PCRX)

SmarTrend identified an Uptrend for Pacira Pharmaceu (NASDAQ:PCRX) on September 25th, 2019 at $39.26. In approximately 2 months, Pacira Pharmaceu has returned 16.05% as of today's recent price of $45.56....

PCRX : 45.54 (-1.39%)
Look for Shares of Pacira Pharmaceu to Potentially Pullback after Yesterday's 1.25% Rise

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $45.57 to a high of $46.25. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

PCRX : 45.54 (-1.39%)
Pacira BioSciences to Present at the 31st Annual Piper Jaffray Healthcare Conference

Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the 31 Annual Piper Jaffray Healthcare Conference at 9:30 AM on Tuesday, December 3, 2019. Live audio of the event can be...

PCRX : 45.54 (-1.39%)
SmarTrend Watching for Potential Pullback in Shares of Pacira Pharmaceu After 1.20% Gain

Pacira Pharmaceu (NASDAQ:PCRX) traded in a range yesterday that spanned from a low of $42.69 to a high of $43.44. Yesterday, the shares gained 1.2%, which took the trading range above the 3-day high...

PCRX : 45.54 (-1.39%)
Interesting PCRX Put And Call Options For January 2020

Investors in Pacira BioSciences Inc saw new options begin trading this week, for the January 2020 expiration. At Stock Options Channel, our YieldBoost formula has looked up and down the PCRX options...

PCRX : 45.54 (-1.39%)
Pacira BioSciences to Present at the Jefferies 2019 London Healthcare Conference

Pacira BioSciences, Inc. (NASDAQ: PCRX) today reported that it will present at the Jefferies 2019 London Healthcare Conference at 2:40 PM GMT (9:40AM ET) on Wednesday, November 20, 2019. Live audio of...

PCRX : 45.54 (-1.39%)
Pacira's (PCRX) Q3 Earnings Top Estimates, Revenues Rise Y/Y

Pacira's (PCRX) third-quarter results reflect an earnings beat while revenues almost match estimates. Exparel drives year-over-year growth.

JNJ : 140.98 (+0.71%)
TRIL : 0.38 (+19.34%)
PTLA : 27.15 (-2.58%)
PCRX : 45.54 (-1.39%)
Pacira (PCRX) Q3 Earnings Surpass Estimates

Pacira (PCRX) delivered earnings and revenue surprises of 41.18% and -0.33%, respectively, for the quarter ended September 2019. Do the numbers hold clues to what lies ahead for the stock?

PCRX : 45.54 (-1.39%)

Barchart Technical Opinion

The Barchart Technical Opinion rating is a 88% Buy with a Average short term outlook on maintaining the current direction.

See More Share

Trade PCRX with:

Business Summary

Pacira Pharmaceuticals, Inc. is a specialty pharmaceutical company focused on the development, commercialization and manufacture of new pharmaceutical products, based on its proprietary DepoFoam drug delivery technology, for use in hospitals and ambulatory surgery centers. Pacira Pharmaceuticals, Inc....

See More

Key Turning Points

2nd Resistance Point 46.84
1st Resistance Point 46.19
Last Price 45.54
1st Support Level 45.09
2nd Support Level 44.64

See More

52-Week High 49.50
Last Price 45.54
Fibonacci 61.8% 43.82
Fibonacci 50% 42.07
Fibonacci 38.2% 40.32
52-Week Low 34.64

See More

Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
Read About Upcoming
Changes to This Feature
Need More Chart Options?
Right-click on the chart to open the Interactive Chart menu.

Free Barchart Webinar